CXO概念股强势凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现_老虎社区_美港股上老虎

CXO概念股强势凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现

金吾财讯03-31

金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2623379186?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","is_english":false,"pubTime":"2026-03-31 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623379186","market":"us","top_or_hot":-1,"title":"CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现","media":"金吾财讯","content":"<html><body><p>金吾财讯 | CXO概念股强势，<a href=\"https://laohu8.com/S/002821\">凯莱英</a>(06821)涨13.85%，<a href=\"https://laohu8.com/S/603127\">昭衍新药</a>(06127)涨7.34%，<a href=\"https://laohu8.com/S/02269\">药明生物</a>(02269)涨5.99%，<a href=\"https://laohu8.com/S/300759\">康龙化成</a>(03759)涨4.54%，<a href=\"https://laohu8.com/S/603259\">药明康德</a>(02359)涨4.12%，<a href=\"https://laohu8.com/S/300347\">泰格医药</a>(03347)涨2.89%，<a href=\"https://laohu8.com/S/01548\">金斯瑞生物科技</a>(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-31 10:23 北京时间&nbsp;&nbsp;&nbsp;<a href=1977810><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏...</p>\n\n<a href=\"1977810\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0307460666.USD","symbol_name":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","start_time":0,"source_url":"1977810","article_id":"2623379186","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623379186","pubTimestamp":1774923794,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","03759":"康龙化成","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426480.USD":"法巴中国股票经典Dis","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1589":"北水核心资产","06127":"昭衍新药","LU0823426308.USD":"法巴中国股票基金","03347":"泰格医药","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","01548":"金斯瑞生物科技","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0051755006.USD":"摩根大通中国A (dist)","02269":"药明生物","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","BK1576":"医药外包概念","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","CXO":"康休","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","02359":"药明康德","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","002821":"凯莱英","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","06821":"凯莱英","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK1521":"挪威政府全球养老基金持仓","LU0140636845.USD":"施罗德大中华区股票A Acc"},"translate_title":"CXO concept stocks are strong Asymchem (06821) rose 13.85% Institutions believe that the inflection point of CXO fundamentals has appeared","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":0.9,"06821":1.5,"03759":0.9,"002821":1.5,"02359":0.9,"02269":0.9,"CXO":1.5,"06127":0.9,"01548":0.9},"content_text":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}